Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (INO) INOVIO PHARMACEUTICALS Posts Q3 Revenue $291.7M

11/09/2021 | 04:25pm EST


ę MT Newswires 2021
All news about INOVIO PHARMACEUTICALS, INC.
01/21BofA Securities Upgrades Inovio Pharmaceuticals to Neutral From Underperform, Adjusts P..
MT
2021Jefferies Assumes Inovio Pharmaceuticals at Hold, $6 Price Target
MT
2021INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunother..
PR
2021INOVIO Updates on Phase 3 Program for VGX-3100 for HPV-Associated Cervical High-Grade S..
CI
2021Inovio Pharmaceuticals Evaluates Two COVID-19 Vaccine Candidates Against Omicron Varian..
MT
2021INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants
PR
2021Thinking about buying stock in Adagio Therapeutics, 180 Life Sciences, InMed Pharmaceut..
PR
2021Novavax developing vaccine that targets new COVID-19 variant
RE
2021Novavax developing vaccine that targets new COVID-19 variant
RE
2021Inovio Pharmaceuticals Begins Dosing in Phase 1 Trial of Ebola Vaccine
MT
More news
Analyst Recommendations on INOVIO PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 1,46 M - -
Net income 2021 -261 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,20x
Yield 2021 -
Capitalization 850 M 850 M -
Capi. / Sales 2021 582x
Capi. / Sales 2022 6,50x
Nbr of Employees 262
Free-Float -
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | INO | US45773H2013 | MarketScreener
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 4,04 $
Average target price 13,88 $
Spread / Average Target 243%
EPS Revisions
Managers and Directors
J. Joseph Kim President, Chief Executive Officer & Director
Peter D. Kies Chief Financial Officer
Simon X. Benito Chairman
Laurent M. Humeau Chief Scientific Officer
Kate E. Broderick Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
INOVIO PHARMACEUTICALS, INC.-19.04%850
MODERNA, INC.-38.07%63 777
LONZA GROUP AG-19.59%49 711
IQVIA HOLDINGS INC.-13.62%46 556
SEAGEN INC.-16.20%23 689
ICON PUBLIC LIMITED COMPANY-17.32%20 842